## Europäisches Patentamt European Patent Office Office européen des brevets

(11) **EP 1 354 601 A8** 

(2) CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)

INID code(s) 30

(48) Corrigendum issued on: **04.02.2004 Bulletin 2004/06** 

(43) Date of publication:22.10.2003 Bulletin 2003/43

(21) Application number: 01273283.0

(22) Date of filing: 17.12.2001

(51) Int Cl.<sup>7</sup>: **A61K 45/00**, A61K 31/198, A61K 31/22, A61K 31/223, A61K 31/255, A61P 27/02, A61P 37/06, A61P 43/00, A23L 1/30

(86) International application number: PCT/JP2001/011054

(87) International publication number:WO 2002/056911 (25.07.2002 Gazette 2002/30)

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 26.12.2000 JP 2000394755

(71) Applicant: Ajinomoto Co., Inc. Tokyo 104-8315 (JP)

(72) Inventors:

 HAMURO, Junji Yokohama-shi Kanagawa 241-0813 (JP)  MURATA, Yukie c/o Ajinomoto Co., Inc. Kawasaki-shi, Kanagawa 210-0801 (JP)

 YAMADA, Jun Otokuni-gun, Kyoto 618-0091 (JP)

 SANO, Yoichiro Kyoto-shi, Kyoto 604-0804 (JP)

KINOSHITA, Shigeru
 Osaka-shi, Osaka 545-0035 (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

## (54) TRANSPLANTATION REJECTION INHIBITORS

(57)The present invention provides a transplant rejection suppressor usable as pharmaceuticals (oral preparations, eye drops, injections, infusions and the like) effective for suppressive treatment of human organ transplant rejection by detecting an oxidized and/or reduced glutathione content in macrophage cells using a body fluid/cell sample separated and collected from human beings to classify macrophages into oxidative macrophages and reductive macrophages different from each other in function, and artificially deviating the presence ratio thereof to oxidative macrophages with a specific low-molecular compound or artificially removing reductive macrophages, and further provides a use of the active ingredient for this purpose or a method for suppressing transplant rejection.

Moreover, the invention can suppress the transplant rejection using the transplant rejection suppressor and also can provide foods, drinks (health foods and the like), nutriments and the like useful for suppressing the transplant rejection.

Especially, the invention can effectively inhibit (suppress) the rejection of the transplantation for the purpose of treatment, improvement and/or prevention of diseases accompanied by rejection in transplantation of human organs such as human liver, heart, lung, kidney, skin, cornea and corneal epithelium and stem cell transplantation of tissues, especially the organ transplantation.

EP 1 354 601 A8